Bio-Techne Corp stock is trading -30.08% below its average target price of $69.26 after dropping -2.9% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $51.0 to $90.0 per share.
The stock has an average amount of shares sold short at 5.3%, and a short ratio of 3.14. Since 1.06% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 105.6% of Bio-Techne Corp's shares being owned by this investor type.
Institutions Invested in Bio-Techne Corp
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 12% | 18,526,824 | $897,161,438 |
| 2025-03-31 | Blackrock Inc. | 9% | 13,746,351 | $665,667,036 |
| 2025-03-31 | Price (T.Rowe) Associates Inc | 7% | 11,375,279 | $550,847,876 |
| 2025-03-31 | State Street Corporation | 4% | 6,529,887 | $316,209,772 |
| 2025-03-31 | Morgan Stanley | 4% | 5,719,540 | $276,968,720 |
| 2025-03-31 | Select Equity Group, Inc. | 3% | 5,366,003 | $259,848,691 |
| 2025-03-31 | Invesco Ltd. | 3% | 4,190,115 | $202,906,315 |
| 2025-03-31 | Geode Capital Management, LLC | 3% | 4,093,398 | $198,222,795 |
| 2025-03-31 | Ameriprise Financial, Inc. | 2% | 3,587,366 | $173,718,195 |
| 2025-03-31 | BAMCO Inc. | 2% | 3,275,806 | $158,630,903 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Bio-Techne Corp.
